Zhao Yongsheng, Zheng Renyan, Chen Jian, Ning Dong
Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Maoyuan South Road, No. 1, Nanchong, 637000 Sichuan China.
Department of Anorectal Medicine, Affiliated Hospital of North Sichuan Medical College, Maoyuan South Road, No. 1, Nanchong, 637000 Sichuan China.
Cancer Cell Int. 2020 Jul 6;20:289. doi: 10.1186/s12935-020-01390-w. eCollection 2020.
Cisplatin (DDP) is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and long-term DDP stimulation increased resistance of NSCLC cells to this drug by enriching cancer stem cells (CSCs), which contributed to recurrence and worse prognosis of NSCLC, but the molecular mechanisms are still not fully delineated.
Real-Time qPCR and Western Blot analysis were conducted to examine gene expressions at mRNA and protein levels, respectively. Dual-luciferase reporter gene system was used to validate the targeting sites among circRNA CDR1as, miR-641 and HOXA9 mRNA. Cell growth was evaluated by CCK-8 assay, trypan blue staining assay and colony formation assay. The Annexin V-FITC/PI double staining method was employed to measure cell apoptosis ratio. Spheroid formation and flow cytometer assay was used to evaluate cell stemness. Xenograft mice models were established to measure tumorgenicity in vivo, and Ki67 expressions in mice tumor tissues were examined by immunohistochemistry (IHC).
Here we identified a novel circRNA CDR1as/miR-641/Homeobox protein Hox-A9 (HOXA9) pathway regulated stemness and DDP chemoresistance in NSCLC. Mechanistically, circRNA CDR1as and HOXA9 were high-expressed, while miR-641 was low-expressed in DDP-resistant NSCLC cells, instead of their corresponding parental DDP-sensitive NSCLC cells. Additionally, we validated that circRNA CDR1as positively regulated HOXA9 in NSCLC cells by serving as an RNA sponge for miR-641, and knock-down of circRNA CDR1as increased the sensitivity of DDP-resistant NSCLC cells, which were reversed by downregulating miR-641 and upregulating HOXA9. Consistently, overexpression of circRNA CDR1as increased drug resistance of DDP-sensitive NSCLC cells by regulating miR-641/HOXA9 axis. In addition, the expression levels of stemness signatures (SOX2, OCT4 and Nanog) were higher in DDP-resistant NSCLC cells, which also tended to form spheres and enrich CD44CD166 population compared to their parental DDP-sensitive NSCLC cells, suggesting that CSCs were enriched in DDP-resistant NSCLC cells. Notably, knock-down of circRNA CDR1as inhibited stemness of DDP-resistant NSCLC cells by inhibiting HOXA9 through upregulating miR-641.
Taken together, this study identified that circRNA CDR1as regulated stemness and DDP chemoresistance in NSCLC cells by targeting miR-641/HOXA9 axis.
顺铂(DDP)是治疗非小细胞肺癌(NSCLC)的一线化疗药物,长期的DDP刺激通过富集癌症干细胞(CSC)增加了NSCLC细胞对该药物的耐药性,这导致了NSCLC的复发和更差的预后,但其分子机制仍未完全阐明。
分别进行实时定量PCR和蛋白质免疫印迹分析以检测mRNA和蛋白质水平的基因表达。采用双荧光素酶报告基因系统验证环状RNA CDR1as、miR-641和HOXA9 mRNA之间的靶向位点。通过CCK-8法、台盼蓝染色法和集落形成试验评估细胞生长。采用膜联蛋白V-FITC/PI双染色法测定细胞凋亡率。采用球状体形成和流式细胞仪检测评估细胞干性。建立异种移植小鼠模型以测量体内肿瘤发生能力,并通过免疫组织化学(IHC)检测小鼠肿瘤组织中Ki67的表达。
在此我们鉴定了一种新的环状RNA CDR1as/miR-641/同源盒蛋白Hox-A9(HOXA9)通路,其调节NSCLC中的干性和DDP化疗耐药性。机制上,环状RNA CDR1as和HOXA9在DDP耐药的NSCLC细胞中高表达,而miR-641低表达,与其相应的亲本DDP敏感的NSCLC细胞相反。此外,我们验证了环状RNA CDR1as通过作为miR-641的RNA海绵在NSCLC细胞中正向调节HOXA9,敲低环状RNA CDR1as增加了DDP耐药NSCLC细胞的敏感性,而下调miR-641和上调HOXA9可逆转这种敏感性。一致地,环状RNA CDR1as的过表达通过调节miR-641/HOXA9轴增加了DDP敏感NSCLC细胞的耐药性。此外,干性标志物(SOX2、OCT4和Nanog)的表达水平在DDP耐药的NSCLC细胞中更高,与它们的亲本DDP敏感的NSCLC细胞相比,这些细胞也倾向于形成球状体并富集CD44CD166群体,表明CSC在DDP耐药的NSCLC细胞中富集。值得注意的是,敲低环状RNA CDR1as通过上调miR-641抑制HOXA9来抑制DDP耐药NSCLC细胞的干性。
综上所述,本研究鉴定了环状RNA CDR1as通过靶向miR-641/HOXA9轴调节NSCLC细胞的干性和DDP化疗耐药性。